Cargando…

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

OBJECTIVE: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. METHODS: We performed a prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Yacovo, Silvana, Saumoy, Maria, Sánchez-Quesada, José Luís, Navarro, Antonio, Sviridov, Dmitri, Javaloyas, Manuel, Vila, Ramon, Vernet, Anton, Low, Hann, Peñafiel, Judith, García, Benito, Ordoñez-Llanos, Jordi, Podzamczer, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446923/
https://www.ncbi.nlm.nih.gov/pubmed/32817629
http://dx.doi.org/10.1371/journal.pone.0237739
_version_ 1783574217406545920
author Di Yacovo, Silvana
Saumoy, Maria
Sánchez-Quesada, José Luís
Navarro, Antonio
Sviridov, Dmitri
Javaloyas, Manuel
Vila, Ramon
Vernet, Anton
Low, Hann
Peñafiel, Judith
García, Benito
Ordoñez-Llanos, Jordi
Podzamczer, Daniel
author_facet Di Yacovo, Silvana
Saumoy, Maria
Sánchez-Quesada, José Luís
Navarro, Antonio
Sviridov, Dmitri
Javaloyas, Manuel
Vila, Ramon
Vernet, Anton
Low, Hann
Peñafiel, Judith
García, Benito
Ordoñez-Llanos, Jordi
Podzamczer, Daniel
author_sort Di Yacovo, Silvana
collection PubMed
description OBJECTIVE: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. METHODS: We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time. RESULTS: The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30–43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values. CONCLUSIONS: In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness.
format Online
Article
Text
id pubmed-7446923
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-74469232020-08-31 Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study Di Yacovo, Silvana Saumoy, Maria Sánchez-Quesada, José Luís Navarro, Antonio Sviridov, Dmitri Javaloyas, Manuel Vila, Ramon Vernet, Anton Low, Hann Peñafiel, Judith García, Benito Ordoñez-Llanos, Jordi Podzamczer, Daniel PLoS One Research Article OBJECTIVE: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. METHODS: We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time. RESULTS: The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30–43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values. CONCLUSIONS: In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness. Public Library of Science 2020-08-20 /pmc/articles/PMC7446923/ /pubmed/32817629 http://dx.doi.org/10.1371/journal.pone.0237739 Text en © 2020 Di Yacovo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Di Yacovo, Silvana
Saumoy, Maria
Sánchez-Quesada, José Luís
Navarro, Antonio
Sviridov, Dmitri
Javaloyas, Manuel
Vila, Ramon
Vernet, Anton
Low, Hann
Peñafiel, Judith
García, Benito
Ordoñez-Llanos, Jordi
Podzamczer, Daniel
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
title Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
title_full Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
title_fullStr Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
title_full_unstemmed Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
title_short Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
title_sort lipids, biomarkers, and subclinical atherosclerosis in treatment-naive hiv patients starting or not starting antiretroviral therapy: comparison with a healthy control group in a 2-year prospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446923/
https://www.ncbi.nlm.nih.gov/pubmed/32817629
http://dx.doi.org/10.1371/journal.pone.0237739
work_keys_str_mv AT diyacovosilvana lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT saumoymaria lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT sanchezquesadajoseluis lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT navarroantonio lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT sviridovdmitri lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT javaloyasmanuel lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT vilaramon lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT vernetanton lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT lowhann lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT penafieljudith lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT garciabenito lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT ordonezllanosjordi lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy
AT podzamczerdaniel lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy